Research work · 2016

Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial

Laurie Helen Sehn, Neil Sun Chua, Jiřı́ Mayer, Greg Dueck, Marek Trněný, Kamal Bouabdallah, Nathan Hale Fowler, Vincent Delwail, Oliver W. Press, Gilles Salles, John G. Gribben, Anne L. Lennard, Pieternella Johanna Lugtenburg, Natalie Dimier, Elisabeth Wassner-Fritsch, Günter Fingerle‐Rowson, Bruce D. Cheson

The Lancet Oncology

DOI: 10.1016/s1470-2045(16)30097-3